Advanced Blood Test Statistics in US 2026 | Panels, Market & Facts

Advanced Blood Test in America 2026

The landscape of advanced blood testing in America has never been more dynamic than it is in 2026. What was once a routine annual check has evolved into a sophisticated, multi-panel diagnostic process that now sits at the very center of preventive healthcare in the United States. From comprehensive metabolic panels (CMP) and complete blood count (CBC) tests to cutting-edge HbA1c screenings, lipid panels, and next-generation genetic diagnostic blood tests, the sheer scale and scope of blood testing activity across the nation tells a compelling story about how Americans are managing chronic disease, monitoring metabolic health, and embracing early detection. With over 320,000 CLIA-certified laboratories operating across all 50 states and territories as of 2021 data (Centers for Medicare & Medicaid Services), and billions of tests processed every single year, advanced blood testing in the US in 2026 is not just a healthcare procedure — it is a nationwide public health infrastructure.

What makes 2026 particularly significant for blood diagnostics is the convergence of several powerful forces: a surging chronic disease burden (with 194 million American adults living with at least one chronic condition per CDC/BRFSS 2023 data), a rapidly expanding US blood testing market valued at $38.37 billion in 2025, and a federal spending landscape where Medicare Part B alone spent $8.4 billion on clinical diagnostic laboratory tests in 2024 — a 5% year-over-year increase (HHS Office of Inspector General, January 2026). This article draws exclusively on verified, confirmed data from US government agencies including the CDC, NCHS, CMS, HHS-OIG, and the American Heart Association’s 2026 Statistics Update, to give you the most accurate, up-to-date picture of advanced blood test statistics in America in 2026.

Interesting Facts About Advanced Blood Tests in the US 2026

Source: CDC National Diabetes Statistics Report (January 2026); CDC/BRFSS Chronic Conditions Report 2025; HHS-OIG Medicare Part B Lab Test Data Snapshot (January 2026); CMS CLIA Program Data; AHA 2026 Heart Disease and Stroke Statistics Update; Market Data Forecast Clinical Laboratory Tests Market Report 2026

These numbers reveal just how deeply advanced blood testing is woven into the fabric of American healthcare in 2026. The fact that 12% of the entire US population — 40.1 million people — is living with diabetes, with nearly 27.6% undiagnosed, underscores why blood tests like the HbA1c (hemoglobin A1c) and fasting plasma glucose are not optional screenings but medical necessities for millions of families. At the same time, the staggering figure of 115 million Americans with prediabetes points to an enormous unmet diagnostic demand — the vast majority of these individuals will require repeated blood glucose monitoring, metabolic panel testing, and follow-up comprehensive blood work before a formal diabetes diagnosis is made. The fact that approximately 75% of all clinical treatment decisions in the US are informed by laboratory test results speaks directly to just how central blood panels are to the entire American medical decision-making ecosystem.

What stands out most in 2026 is the dramatic shift in Medicare lab spending behavior. While traditional non-genetic blood tests — CMP panels, CBC, lipid panels, and thyroid function tests (TSH) — have been declining in Medicare Part B spending since 2021, genetic and PCR-based infectious disease blood tests have exploded, now accounting for 43% of all Medicare Part B lab spending at $3.6 billion in 2024. Genetic test spending alone rose 20% between 2023 and 2024 (HHS-OIG), and 346 laboratories each received over $1 million in Medicare reimbursements for genetic tests in 2024. This tells a very important story: advanced blood testing in America is rapidly expanding beyond traditional chemistry panels into the realm of molecular diagnostics, genomic screening, and precision medicine — signaling a fundamental transformation in what “advanced blood testing” means in 2026.

Blood Testing Market Size & Growth in the US 2026

Source: Research and Markets — U.S. Blood Testing Market Size, Share & Forecast Report (2025–2033)

The US blood testing market is on a powerful, sustained growth trajectory that few healthcare segments can match in 2026. Valued at $38.37 billion in 2025, the market is projected to nearly double to $71.41 billion by 2033, advancing at a compound annual growth rate of 8.1% over the forecast period (Research and Markets). This relentless expansion is being driven by a uniquely American combination of forces — a rapidly aging population, a chronic disease epidemic that demands continuous monitoring, substantial government investment in preventive care, and the emergence of breakthrough diagnostic technologies including AI-powered blood test interpretation, lab-on-a-chip miniaturization, and wearable biosensor integration with telemedicine platforms. The US market consistently represents the largest share of the global blood testing landscape, with North America commanding approximately 44.83% of the global blood testing market in 2024 (Grand View Research), a position of dominance that reflects America’s unmatched healthcare infrastructure and testing volumes.

Looking at the clinical laboratory tests market more broadly in the US, the figures paint an even bigger picture. The US clinical laboratory tests market was valued at approximately $46.89 billion in 2025 (Precedence Research, February 2026) and is projected to grow at a CAGR of 9.31% through 2035, reaching $114.19 billion. This growth is underpinned by the increasing burden of metabolic diseases like diabetes, chronic kidney disease, liver disease, and cardiovascular conditions — all of which require frequent, sophisticated blood panel testing for ongoing patient management. What’s particularly significant in the current landscape is the US market’s 40.2% share of the global clinical laboratory tests market in 2025, with North America retaining dominance through its advanced regulatory framework (FDA 510(k) clearance for lab equipment), robust health insurance coverage, and exceptionally high per-capita diagnostic testing volumes that are unmatched anywhere in the world.

Advanced Blood Test Panels Usage Statistics in the US 2026

Source: Market Data Forecast Clinical Laboratory Tests Market Report (2026); Grand View Research Blood Testing Market Report; Precedence Research Clinical Laboratory Tests Market (Feb 2026); HHS-OIG Medicare Part B Lab Test Data Snapshot (Jan 2026); Coherent Market Insights Blood Testing Market 2026

The panel-by-panel breakdown of advanced blood testing in the US reveals a market that is simultaneously mature in its foundational tests and explosively innovative at its growth edge. Complete Blood Count (CBC) retains its position as the dominant test type globally with a 26.9% market share in 2025, owing to its indispensability in routine annual physicals, pre-operative assessments, emergency triage, and monitoring of chronic conditions — its ubiquity is explicitly supported by CDC clinical guidelines which underpin its consistent high-volume ordering across every care setting in America. HbA1c testing holds the top market share position driven by the extraordinary burden of diabetes and prediabetes in the United States, with over 155 million Americans either diabetic or prediabetic requiring glycemic monitoring. The lipid panel, meanwhile, commanded 12.46% of the US clinical laboratory tests market revenue in 2024, reflecting how heavily cardiovascular risk assessment is embedded in standard American preventive care protocols given the 915,973 cardiovascular disease deaths recorded in 2023 (AHA 2026 Statistics).

The most striking structural shift in advanced blood testing in 2026 is the dominance of genetic and PCR-based tests within the Medicare reimbursement landscape. In just six years — between 2018 and 2024 — the share of Medicare Part B spending dedicated to genetic lab tests jumped from 18% to 43% (HHS-OIG). Of the top 25 Medicare lab tests by expenditure in 2024, 10 were genetic or PCR infectious disease tests totaling $1.5 billion in Part B spending, with the single highest-expenditure test being CPT code 87798 (infectious organism detection), which drew $442.5 million in Medicare payments — a staggering 51% increase from 2023. Six of the top ten genetic tests in 2024 showed at least a 30% increase in Part B spending year-over-year, confirming that molecular and genomic blood diagnostics are now a core pillar of advanced blood testing in America — not a niche add-on.

Chronic Disease Burden & Blood Diagnostic Demand in the US 2026

Source: CDC National Diabetes Statistics Report (January 21, 2026); CDC NCHS Data Brief No. 516 (November 2024); CDC Preventing Chronic Disease Journal — Watson et al. (2025); AHA 2026 Heart Disease and Stroke Statistics Update (Circulation, 2026); CDC NHIS Circulatory Disease Risk Factors Study (PMC, 2025)

The chronic disease statistics driving blood test demand in the US in 2026 are nothing short of alarming in scale. 40.1 million Americans — including 28.8% of all adults aged 65 and older — are living with diabetes as of the most recent CDC National Diabetes Statistics Report released January 21, 2026. Critically, 11 million of those diabetics (27.6%) remain completely undiagnosed, meaning their conditions are only identifiable through proactive blood testing — specifically HbA1c and fasting plasma glucose measurements. What is even more remarkable is that 115 million American adults — more than one in three — are in the prediabetic range, creating an extraordinary ongoing demand for metabolic blood panels as the healthcare system tries to catch these cases before they progress. Among those aged 20 and older, total diabetes prevalence was 15.8% during August 2021–August 2023 (CDC NCHS Data Brief No. 516), with diagnosed diabetes at 11.3% and undiagnosed at 4.5%, confirming that millions of routine annual blood tests are capturing conditions Americans don’t know they have.

The cardiovascular picture in the AHA’s 2026 Heart Disease and Stroke Statistics Update adds another urgent dimension to blood diagnostic demand. With 915,973 Americans dying from cardiovascular disease in 2023 — and the AHA highlighting worsening trends in blood pressure, cholesterol, and glucose control as key drivers — the demand for lipid panels, cardiac biomarker testing, and comprehensive blood chemistry panels among the tens of millions of Americans managing hypertension, dyslipidemia, and metabolic syndrome is not declining. High cholesterol prevalence has risen significantly from 20.1% to 22% of US adults between 2019 and 2022 (CDC NHIS data), and the 2026 AHA Statistics Update notes that declines in core health factors including cholesterol and blood pressure control are fueling a resurgence in cardiovascular risk — directly translating to more frequent, more advanced blood testing at every point of care across America.

Medicare & Government Lab Test Spending on Blood Tests in the US 2026

Source: HHS Office of Inspector General — Data Snapshot: Total Medicare Part B Spending on Lab Tests Rose in 2024 (January 28, 2026); OIG Medicare Part B Lab Test Report December 2024

The Medicare Part B laboratory test spending data published by the HHS Office of Inspector General on January 28, 2026 is one of the most authoritative and data-rich government sources on blood test economics in America. The headline figure — $8.4 billion in total Medicare Part B lab spending in 2024, a 5% increase from 2023 — represents a milestone reversal after spending had declined post-COVID in 2023. But the structural story within that number is even more significant: while spending on traditional non-genetic blood tests (metabolic panels, lipid panels, CBCs, thyroid tests) has been generally declining since 2021, dropping to $4.8 billion in 2024, spending on genetic blood tests grew by 20% in a single year — from $3.0 billion in 2023 to $3.6 billion in 2024. This genetic test spending now represents 43% of all Medicare Part B lab spending, up from just 18% in 2018 — a transformational shift in the composition of what “advanced blood testing” means to the American healthcare system.

The concentration of spending within the top 25 Medicare lab tests is equally striking: those 25 test codes alone accounted for $4.1 billion — nearly 50% of all Part B lab spending in 2024. The single highest-expenditure test was CPT code 87798 (infectious organism genetic detection), totaling $442.5 million with a 51% increase from 2023, and a median payment of $447 per claim. Among the top 25, 10 were genetic or PCR infectious disease tests totaling $1.5 billion, while the remaining 15 traditional blood tests totaled $2.6 billion — showing that despite the genetic surge, foundational blood chemistry tests like the CMP (CPT 80053), lipid panel (CPT 80061), and TSH (CPT 84443) remain the bedrock of Medicare laboratory spending, and have held positions in the top 3–4 Medicare tests by expenditure consistently since 2018. The 346 laboratories that each received over $1 million in Medicare payments for genetic tests alone in 2024 — including 55 labs receiving over $10 million — signals an intensely competitive and rapidly professionalizing genetic testing industry in America.

CLIA-Certified Laboratory Infrastructure for Blood Testing in the US 2026

Source: CMS Clinical Laboratory Improvement Amendments (CLIA) Program Data; Centers for Medicare & Medicaid Services QIES Database; PMC National Institutes of Health Study — “Estimation of Numbers of Testing Personnel and Test Volume in CLIA Laboratories” (April 2024); Bureau of Labor Statistics

The CLIA-certified laboratory infrastructure that underpins all advanced blood testing in America is staggering in its scale and complexity. Over 320,000 CLIA-certified facilities are currently active across all US states and territories, regulated by the Centers for Medicare & Medicaid Services (CMS) to ensure consistent quality standards in every specimen processed on American soil. Of these, the ~33,000 Certificate of Accreditation and Certificate of Compliance laboratories — which include hospital labs, large independent reference labs, and physician office labs — are responsible for processing more than 90% of all clinical tests in the United States. What makes this infrastructure unique is the three-tier verification system: the College of American Pathologists (CAP) and COLA together accredit labs covering 76% of all complex testing, ensuring that the results feeding into clinical decisions for millions of patients meet rigorous quality benchmarks. An estimated 328,000 testing personnel staff these facilities daily, cross-validated against Bureau of Labor Statistics employment data for clinical laboratory technologists and technicians.

The breakdown of laboratory types reveals a highly distributed and decentralized blood testing system. The ~120,000 physician office laboratories — by far the largest category numerically — bring basic blood testing directly into primary care settings, enabling point-of-care CBC, glucose, and basic metabolic screening at the point of clinical encounter. The ~9,000 hospital laboratories handle the highest complexity testing for inpatient and emergency cases, while the ~7,000 independent reference laboratories — including national giants like Quest Diagnostics and Labcorp — process enormous volumes of specialized and advanced blood panels for healthcare providers nationwide. The CMS regulatory framework operates on a biennial inspection cycle for CoA and CoC labs, with test volumes self-reported and verified by inspectors during on-site visits — a verification system that directly ties into the CLIA fee structure and ensures accountability at national scale.

Advanced Blood Test Biomarkers & Disease Detection Rates in the US 2026

Source: CDC NCHS Data Brief No. 516 (November 2024); PMC Study — Diabetes Prevalence and Management Patterns in US Adults 2001–2023; AHA 2026 Heart Disease and Stroke Statistics Update (Circulation); Coherent Market Insights Blood Testing Market 2026; PMC — CBC and CVD Study (medrxiv 2024); Coherent Market Insights (Labcorp FDA-cleared Alzheimer’s Blood Test, August 2025)

The biomarker and disease detection data at the heart of advanced blood testing in 2026 exposes the true clinical stakes of routine and specialized blood work in America. Perhaps no single data point better captures the systemic urgency than this: HbA1c levels below the optimal threshold of 7% are only achieved by 44.9% of US adults with diabetes as of the most recent NHANES cycles (2021–2023) — a dramatic decline from 61.5% in 2001–2002 (PMC study, 2025). This means that despite a mature, nationwide blood testing infrastructure and decades of evidence-based guidelines, the majority of Americans with diabetes are not achieving therapeutic glycemic control, and blood tests are capturing not just diagnoses but a widening treatment gap that represents one of American medicine’s most pressing public health challenges in 2026. The trend data on LDL cholesterol in diabetic adults is similarly sobering: 73.1% had LDL levels above the recommended threshold of 70 mg/dL in the 2017–2020 NHANES cycle, and only half of those individuals were on a statin — showing that lipid panel results are being gathered without always translating into protective treatment.

One of the most significant breakthroughs in advanced blood testing in the current era is the FDA clearance in August 2025 of the Labcorp Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first-ever US FDA-cleared blood test for Alzheimer’s disease. This test, now available nationwide through Labcorp, can detect amyloid plaques in the brain from a simple blood draw, offering a less invasive alternative to lumbar punctures and PET scans, with clinical studies demonstrating predictive values above 90%. This development, alongside a CBC-based cardiovascular risk prediction model validated across six major longitudinal cohorts (Framingham Offspring, Framingham 3rd Gen, MESA, CRIC, and CARDIA), confirms that 2026 marks a genuine inflection point in what advanced blood panels can detect — not just diabetes, cholesterol, and kidney function, but neurological disease, genetic cancer risk, and complex infectious organisms that would have required invasive procedures or extensive imaging just a decade ago.

Advanced Blood Test Technology Trends in the US 2026

Source: Coherent Market Insights Blood Testing Market 2026 (Labcorp Lumipulse FDA Clearance, August 2025); Research and Markets US Blood Testing Market Report 2025–2033; HHS-OIG Medicare Part B Lab Report January 2026; Grand View Research Blood Testing Market 2025–2030; Precedence Research Clinical Laboratory Tests Market February 2026; Market Data Forecast Clinical Laboratory Tests Market 2026

The technology transformation reshaping advanced blood testing in America in 2026 is as profound as any shift in the history of clinical diagnostics. Artificial intelligence integration into blood test interpretation has moved well beyond pilot programs — in 2025, major US healthcare systems including Mayo Clinic successfully deployed AI-assisted imaging and diagnostic tools that reduced diagnostic error rates and accelerated reporting timelines across their laboratory workflows. AI algorithms are now being used to analyze the complex, multivariable outputs of CBC differentials, metabolic panels, and genetic sequencing data at speeds and with pattern-recognition capabilities that exceed traditional manual review, directly improving both sensitivity and specificity in detecting early-stage chronic conditions. The shift toward Point-of-Care (POC) testing — classified as the fastest growing technology segment in the US diagnostics market in 2026 — is equally transformative, with devices like Roche’s COBAS Liat System delivering rapid molecular blood tests for COVID-19, influenza, and infectious organisms directly at the clinical encounter site, bypassing centralized lab wait times entirely.

The wearable biosensor revolution is another defining feature of advanced blood testing in 2026, with devices like Abbott’s FreeStyle Libre enabling real-time, continuous blood glucose monitoring for diabetes patients without repeated venipuncture. Integrated with telemedicine platforms, these devices feed live blood chemistry data directly into care management workflows, enabling a fundamentally new model of continuous blood health surveillance rather than periodic snapshot testing. The emergence of liquid biopsy — detecting cancer biomarkers from a simple blood draw rather than invasive tissue sampling — represents perhaps the most disruptive frontier in advanced blood diagnostics, with companies like Guardant Health driving commercialization in US oncology settings. Combined with the fastest-growing CAGR of HGB/HCT testing (haemoglobin and haematocrit, addressing anemia, sickle cell disease, and RBC disorders), the picture that emerges from 2026’s advanced blood testing landscape is one of extraordinary breadth and depth — a field where a single blood draw can now yield insights that span diabetes, cardiovascular risk, kidney function, liver health, thyroid status, cancer risk, Alzheimer’s markers, and infectious disease genetics simultaneously.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE